Testosterone 2% gel (Testavan®, Testarzon®) in adult male hypogonadism: a profile of its use

  • Katherine A. Lyseng-WilliamsonEmail author
Adis Drug Q&A


Testosterone 2% (20 m/mL) transdermal gel (Testavan®, Testarzon®), is indicated to treat adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. It is applied once daily using a hands-free applicator, with an initial recommended daily dosage equivalent to 23 mg testosterone, which may be increased to 46 or 69 mg/day. In clinical studies, once-daily application of Testavan 2% gel was associated with rapid and extensive absorption of testosterone, leading to normalization of testosterone levels in hypogonadal men. After application, testosterone levels achieve their peak in ≈ 2–4 h, then decrease to pre-application levels at ≈ 12 h, broadly mirroring the natural diurnal rhythm of male testosterone. Testavan 2% gel also improved sexual, physical and mental functioning, fatigue and health-related quality of life. The components of Testavan’s novel gel enhance the transdermal transfer of testosterone into the blood, allowing the application of lower doses of testosterone in smaller gel volumes relative to the application of other transdermal testosterone gels. Testavan 2% gel is applied using the applicator cap rather than by hand, reducing the potential risk of secondary transfer of testosterone.



The manuscript was reviewed by: S. Arver, ANOVA-Andrology, Sexual Medicine and Trans Medicine, Karolinska University Hospital and the Karolinska Institute, Stockholm, Sweden; F.A. Cadegiani, Adrenal and Hypertension Unit, Division of Endocrinology and Metabolism, Department of Medicine, Universidade Federal de São Paulo, São Paulo, Brazil; C.N. Jayasena, Department of Investigative Medicine, Imperial College London, London, UK; N. Karsiyakali, Department of Urology, Ҁukurca State Hospital, Ҁukurca, Hakkâri, Turkey. During the peer review process, Ferring Pharmaceuticals Ltd, the marketing-authorization holder of Testavan, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

KA. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.


  1. 1.
    Dohle GR, Arver S, Bettocchi C, et al. EAU guidelines on male hypogonadism. 2018. Accessed 2019.
  2. 2.
    Morales A, Bebb RA, Manjoo P, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ. 2015;187(18):1369–77.CrossRefGoogle Scholar
  3. 3.
    Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male: diagnosis, potential benefits, and risk of testosterone replacement therapy. Int J Endocriol. 2012;2012:625434. Scholar
  4. 4.
    Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Clin Endocrinol Metab. 2018;103(5):1715–44.CrossRefGoogle Scholar
  5. 5.
    Täuber U, Schröder K, Düsterberg B, et al. Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet. 1986;11(2):145–9.CrossRefGoogle Scholar
  6. 6.
    Arver S, Stief C, de la Rosette J, et al. A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology. 2018;6(3):396–407.CrossRefGoogle Scholar
  7. 7.
    Ullah M, Riche DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014;8:101–12.Google Scholar
  8. 8.
    Testavan® 20 mg/g transdermal gel: summary of product characteristics and patient leaflet. West Drayton: Ferring Pharmaceuticals; 2018.Google Scholar
  9. 9.
    Alberti I, Grenier A, Kraus H, et al. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv. 2005;2(5):935–50.CrossRefGoogle Scholar
  10. 10.
    Efros M, Carrara D, Neijber A. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies. Andrologia. 2016;48(6):637–45.CrossRefGoogle Scholar
  11. 11.
    Olsson H, Sandstrom R, Neijber A, et al. Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel(R) in healthy men. Clin Pharmacol Drug Dev. 2014;3(5):358–64.CrossRefGoogle Scholar
  12. 12.
    Testogel® 50 mg, gel in sachet: summary of product characteristics and patient leaflet. London: Besin Healthcare (UK) Ltd; 2018.Google Scholar
  13. 13.
    Belkoff L, Brock G, Carrara D, et al. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: phase III open-label studies. Andrologia. 2018;50(1):e12801.CrossRefGoogle Scholar
  14. 14.
    Cunningham G, Belkoff L, Brock G, et al. Efficacy and safety of a new topical testosterone replacement gel therapy for the treatment of male hypogonadism. Endocr Pract. 2017;23(5):557–65.CrossRefGoogle Scholar
  15. 15.
    Layton JB, Meier CR, Harpless JL, et al. Comparative safety of testosterone dosage forms. JAMA Intern Med. 2015;175:1187–96.CrossRefGoogle Scholar
  16. 16.
    Testim® 50 mg transdermal gel: summary of product characteristics and patient leaflet. West Drayton: Ferring Pharmaceuticals; 2016.Google Scholar
  17. 17.
    Tostran® 2% gel: summary of product characteristics and patient leaflet. Galashiels: Kyowa Kirin Ltd; 2016 .Google Scholar
  18. 18.
    Adis Insight. Testosterone products for hypogonadism. Accessed 20 Feb 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerMairangi BayNew Zealand

Personalised recommendations